BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase
Award Recognizes Technologies That Address Important Industry Needs and Advance Prior Standards
CellSeal CryoCase was developed in response to documented container failures in CGT manufacturing, where flexible cryobags have historically been susceptible to stress fractures and seal fatigue from cycles of controlled rate freezing, liquid nitrogen storage, and distribution. CryoCase provides reinforced structural protection across the full frozen product journey while remaining compatible with closed system manufacturing workflows.
As CGT programs scale toward commercialization, regulators are paying closer attention to how frozen products are handled and inspected. CryoCase supports visual inspection for container integrity and potential particulates while giving manufacturers greater confidence in containment across product development.
"We're pleased to receive this recognition from INTERPHEX, one of the industry's leading forums for pharmaceutical and biotechnology innovation," said
Launched in 2025, CryoCase is available as part of BioLife's CellSeal® portfolio. For more information, visit https://www.biolifesolutions.com/handling/cellseal-cryocase/.
About
Media & Investor Relations
At the Company
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com
Investors
Alliance Advisors IR
(310) 691-7100
jcain@allianceadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-wins-interphex-2026-biotech-innovation-award-for-cellseal-cryocase-302749192.html
SOURCE